Aldeyra’s eye drug found effective in mid-stage study
Aldeyra Therapeutics Inc said its experimental eye drug proved to be more effective than a placebo in treating itching associated with allergic conjunctivitis in a mid-stage study.
Allergic conjunctivitis is a common disease characterized by an inflammation of the membrane that covers the eye, which results in excessive tear production, ocular itching, swelling, and redness.
Aldeyra’s experimental drug, NS2, being evaluated in the 100-patient study, was tested in those patients who had at least two-year history of allergic conjunctivitis triggered by grass, tree or ragweed pollen.
Data from the study showed that both single and multiple doses of the drug were statistically significant over a placebo during the trial.
The drug, NS2, was safe during the trial. However, two patients dropped out of the study, the company said on Monday.
NS2 works by trapping small molecules called aldehydes, that are considered to be one of the reasons for inflammatory conditions including allergic conjunctivitis.
Lexington, Massachusetts-based Aldeyra said it is also testing NS2 for another type of eye infection and Sjögren-Larsson Syndrome, a rare genetic condition characterized by dry, scaly skin, as well as eye and neurological problems.
(Reporting by Rosmi Shaji in Bengaluru; Editing by Savio D’Souza and Shounak Dasgupta)
Source: Reuters Health